Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 10
Submit an article Journal homepage
96
Views
8
CrossRef citations to date
0
Altmetric
Review

Update on antimicrobial agents: new indications of older agents

Timothy R Pasquale Summa Health System, Department of Pharmacy 525 E, Market Street, Akron, OH 44309, USA. [email protected]
&
James S Tan Summa Health System, Department of Internal Medicine, 55 Arch Street Suite 1A, Akron, OH 44309, USA. [email protected]
Pages 1681-1691 | Published online: 08 Aug 2005

Bibliography

  • GORDON KA, BIEDENBACH DJ, JONES RN: Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn. MicrobioL Infect. Dis. (2003) 46(4):285–289.
  • ALTUNAIJI S, KUKURUZOVIC R, CURTIS N, MASSIE J: Antibiotics for whooping cough (pertussis). Cochrane Database Syst. Rev. (2005) (1):CD004404.
  • FRENCH AL, BENATOR DA, GORDIN FM: Nontuberculous mycobacterial infections. Med. Clin. North Am. (1997) 81(2):361–379.
  • LUFT BJ, DATTWYLER RJ, JOHNSON RC et al.: Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial. Ann. Intern. Med. (1996) 124(9):785–791.
  • STRLE F, MARASPIN V, LOTRIC-FURLAN S, RUZIC-SABLJIC E, CIMPERMAN J: Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection (1996) 24(1):64–68.
  • BARSIC B, MARETIC T, MAJERUS L, STRUGAR J: Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection (2000) 28(3):153–156.
  • HOOK EW 3RD, STEPHENS J, ENNIS DM: Azithromycin compared with penicillin G benzathine for treatment of incubating syphilis. Ann. Intern. Med. (1999) 131(0:434–437.
  • VERDON MS, HANDSFIELD HH, JOHNSON RB: Pilot study of azithromycin for treatment of primary and secondary syphilis. Clin. Infect. Dis. (1994) 19(3):486–488.
  • MASHKILLEYSON AL, GOMBERG MA, MASHKILLEYSON N, KUTIN SA: Treatment of syphilis with azithromycin. Int. J. STD AIDS (1996) 7\(Supp1.1):13–15.
  • O'FARRELL N: Donovanosis. Sex. Transm.Infra. (2002) 78(6):452–457.
  • AREVALO MORLES C, HERNANDEZ I, FERREIRO MC: Donovanosis: treatment with azithromycin. Int. J. STD AIDS (1997) 8(1):54–56.
  • MARTIN DH, SARGENT SJ, WENDEL GD Jr et al.: Comparison of azithromycin and ceftriaxone for the treatment of chancroid. Clin. Infect. Dis. (1995) 21(2):409–414.
  • LAHEIJ RJ, ROSSUM LG, JANSEN JB, STRAATMAN H, VERBEEK AL: Evaluation of treatment regimens to cure Hehcobacter pylori infection-a meta-analysis. Aliment Pharmacol Ther. (1999) 13(7):857–864.
  • WALSH JH, PETERSON WL: Drug therapy: the treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl. J. Med. (1995) 333:984–991.
  • LACASSIN F, SCHAFFO D, PERRONNE C, LONGUET P, LEPORT C, VILDE JL: Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus. Anti microb. Agents Chemother. (1995) 39(1):276–277.
  • CONRAD DA: Treatment of cat-scratch disease. Curr. Opin. Pediatr. (2001) 13(1):56–59.
  • IVES TJ, MANZEWITSCH P, REGNERY RL, BUTTS JD, KEBEDE M: In vitro susceptibilities of Bartonella henselae, B. quintana, B. elizabethae, Rickettsia rickettsfi, R. conorii, R. akari, and R. proumzekii to macrolide antibiotics as determined by immunofluorescent-antibody analysis of infected Vero cell monolayers. Anti microb. Agents Chemother. (1997) 41(3):578–582.
  • WEISS LM: Babesiosis in humans: a treatment review. Expert Opin. Pharmacother. (2002) 3(8):1109–1115.
  • KRAUSE PJ: Babesiosis diagnosis and treatment. Vector Borne 7,00notic Dis. (2003) 3(1):45–51.
  • KRAUSE PJ, LEPORE T, SIKAND VK et al.: Atovaquone and azithromycin for the treatment of babesiosis. N Engl. J. Med. (2000) 343:1454–1458.
  • TAYLOR WR, RICHIE TL, FRYAUFF DJ et al.: Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin. Infect. Dis. (1999) 28(1):74–81.
  • ANDERSON SL, BERMAN J, KUSCHNER R et al.: Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann. Intern. Med. (1995) 123(10):771–773.
  • DUNNE MW, BOZZETTE S, MCCUTCHAN JA et al.: Efficacy of azithromycin in prevention of Pneumocystis carinfi pneumonia: a randomised trial. California Collaborative Treatment Group. Lancet (1999) 354(9182):891–895.
  • HUGHES WT, DANKNER WM, YOGEV R et al.: Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin. Infra. Dis. (2005) 40(1):136–145.
  • PASQUALE TR, TAN JS: Nonantimicrobial effects of antibacterial agents. Clin. Infra. Dis. (2005) 40(1):127–135.
  • •Good general review of the non-antimicrobial effects of antibacterial agents.
  • GOTFRIED MH: Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest (2004) 125(2 Suppl.):525–605.
  • KUDOH S: Erythromycin treatment in diffuse panbronchiolitis. Curr. Opin. Pulm. Med. (1998) 4(2):116–121.
  • RUBIN BK, HENKE MO: Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest (2004) 125(2 Suppl.):705–785.
  • SAIMAN L, MARSHALL BC, MAYER-HAMBLETT N et al.: Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA (2003) 290(13):1749–1756.
  • PARNHAM MJ: Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr. Opin. Infect. Dis. (2005) 18(2):125–131.
  • ••Comprehensive review of theimmunomodulatory effects of antimicrobials in the therapy of respiratory tract infections.
  • TAMAOKI J, TAKEYAMA K, TAGAYA E, KONNO K: Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob. Agents Chemother. (1995) 39(8):1688–1690.
  • WORMSER GP, NADELMAN RB, DATTWYLER RJ et al.: Practice guidelines for the treatment of Lyme disease. The
  • •• Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 31 (Supp1.1):1–14.
  • YOUNG EJ: Brucella speciea (Brucellosis). In: Antimicrobial therapy and vaccines Volume I. Microbes.VL Yu, R Weber, D Raoult (Eds), Appletree Publications, LLC, New York, NY USA (2002) 121–40.
  • DERESINSKI S: Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. (2005) 40(4):562–573.
  • ••Comprehensive review of MRSA.
  • Vancomycin-resistant Staphylococcus aureus-Pennsylvania. MMWR Morb. Mortal. Wkly. Rep. (2002) 51(40):902.
  • ADRA M, LAWRENCE KR: Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann. Pharmacother. (2004) 38(2):338–341.
  • •Extensive literature review on the use of T-S in the treatment of S. aureus infections.
  • RECOMMENDATIONS FOR PREVENTING THE SPREAD OF VANCOMYCIN RESISTANCE: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm. Rep. (1995) 44(RR-12):1–13.
  • DIEKEMA DJ, PFALLER MA, SCHMITZ FJ et al.: Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin. Infect. Dis. (2001) 32\(Supp1.2):S114–S132.
  • SCHMITZ FJ, KREY A, SADURSKI R,VERHOEF J, MILATOVIC D, FLUIT AC: Resistance to tetracycline and distribution of tetracycline resistance genes in European Staphylococcus aureus isolates. Antimicrob. Chemother. (2001) 47(2):239–240.
  • LAWLOR MT, SULLIVAN MC, LEVITZ RE, QUINTILIANI R, NIGHTINGALE C: Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline. J. Infect. Dis. (1990) 161(4):812–814.
  • NICOLAU DP, FREEMAN CD, NIGHTINGALE CH, COE CJ, QUINTILIANI R: Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (1994) 38(7):1515–1518.
  • RUHE J: Use of tetracyclines for infections caused by methicillin-resistant Staphylococcus aureus. In Program and Abstracts of the 42nd Annual Meeting of the Infectious Disease Society America. Boston, MA, USA (2004) Abstract 516.
  • JONG EC, NOTHDURFT HD: Current drugs for antimalarial chemoprophylaxis: a review of efficacy and safety. J. Travel Med. (2001) 8\(Suppl. 3):548–556.
  • PANG LW, LIMSOMWONG N, BOUDREAU EF, SINGHARAJ P: Doxycycline prophylaxis for falciparum malaria. Lancet (1987) 1(8543):1161–1164.
  • LOBEL HO, KOZARSKY PE: Update on prevention of malaria for travelers. JAMA (1997) 278(21):1767–1771.
  • CENTERS FOR DISEASE CONTROL AND PREVENTION: Health Information for International Travel 2003–2004. Altanta: US Department of Health and Human Services, Public Health Service (2003).
  • RAWAL SY, RAWAL YB: Non-antimicrobial properties of tetracyclines-dental and medical implications. West Indian Med. J. (2001) 50(2):105–108.
  • GOLUB LM, RAIVIAMURTHY NS, MCNAMARA TF, GREENWALD RA, RIFKIN BR: Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit. Rev. Oral Biol. Med. (1991) 2(3):297–321.
  • DUIVENVOORDEN WC, POPOVIC SV, LHOTAK S et al: Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Res. (2002) 62(6):1588–1591.
  • JOHN k TUSZYNSKI G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. PathoL Oncol Res. (2001) 7(1):14–23.
  • SAIKALI Z, SINGH G: Doxycycline and other tetracyclines in the treatment of bone metastasis. Anticancer Drugs (2003) 14(10):773–778.
  • SHAPIRA L, SOSKOLNE WA, HOURI Y, BARAK V, HALABI A, STABHOLZ A: Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect. Immun. (1996) 64(3):825–828.
  • TENG YD, CHOI H, ONARIO RC et al:Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc. Natl. Acad. Sci. USA (2004) 101(9):3071–3076.
  • FAGAN SC, EDWARDS DJ, BORLONGAN CV et ell.: Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. Exp. NeuroL (2004) 186(2):248–251.
  • WELLS JE, HURLBERT RJ, FEHLINGS MG, YONG VW: Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain (2003) 126(Pt 7):1628–1637.
  • YONG VW: Prospects for neuroprotection in multiple sclerosis. Front Biosci. (2004) 9:864–872.
  • MARKOWITZ N, QUINN EL, SARAVOLATZ LD: Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann. Intern. Med. (1992) 117(5):390–398.
  • GODMAN GC, CHURG J: Wegener's granulomatosis: pathology and review of the literature. AMA Arch. PathoL (1954) 58(6):533–553.
  • FAUCI AS, HAYNES BF, KATZ P, WOLFF SM: Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Intern. Med. (1983) 98(1):76–85.
  • TERVAERT JW, VAN DER WOUDE FJ, FAUCI AS et al.: Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch. Intern. Med. (1989) 149(11):2461–2465.
  • STEGEMAN CA, TERVAERT JW, SLUITER WJ, MANSON WL, DE JONG PE, KALLENBERG CG: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann. Intern. Med. (1994) 120(1):12–17.
  • VAN DER WOUDE FJ, RASMUSSEN N, LOBATTO S et al.: Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet (1985) 1(8426):425–429.
  • TERVAERT JW, HUITEMA MG, HENE RJ et al.: Prevention of relapses in
  • •• Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet (1990) 336(8717):709–711.
  • PINCHING AJ, REES AJ, PUSSELL BA, LOCKWOOD CM, MITCHISON RS, PETERS DK: Relapses in Wegener's granulomatosis: the role of infection. Br. Med. J. (1980) 281(6244):836–838.
  • REINHOLD-KELLER E, DE GROOT K, RUDERT H, NOLLE B, HELLER M, GROSS WL: Response to trimethoprim/ sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. Qjm (1996) 89(1):15–23.
  • STEGEMAN CA, TERVAERT JW, DE JONG PE, KALLENBERG CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl. J. Med. (1996) 335(1):16–20.
  • REGAN MJ, HELLMANN DB, STONE JH: Treatment of Wegener's granulomatosis. Rheum. Dis. Clin. North Am. (2001) 27(4):863–886.
  • MANSFIELD LS, GAJADHAR AA Cyclospora cayetanensis, a food- and waterborne coccidian parasite. Vet. ParasitoL (2004) 126(1-2):73–90.
  • HERWALDT BL: Cyclospora cayetanensis: a review, focusing on the outbreaks of cyclosporiasis in the 1990s. Clin. Infect. Dis. (2000) 31(4):1040–1057.
  • HOGE CW, SHLIM DR, GHIMIRE M et al.: Placebo-controlled trial of co-trimoxazole for Cyclospora infections among travellers and foreign residents in Nepal. Lancet (1995) 345(8951):691–693.
  • Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. (2005) 171(4):388–416.
  • GALES AC, JONES RN, FORWARD KR, LINARES J, SADER HS, VERHOEF J: Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin. Infect. Dis. (2001) 32\(Suppl. 2):S104–S113.
  • WOOD GC, HANES SD, CROCE MA, FABIAN TC, BOUCHER BA: Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Clin. Infect. Dis. (2002) 34(11):1425–1430.
  • LEVIN AS, LEVY CE, MANRIQUE AE, MEDEIROS EA, COSTA SF: Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int. J. Antimicrob. Agents (2003) 21(1):58–62.
  • SMOLYAKOV R, BORER A, RIESENBERG K et al.: Nosocomial multi-drug resistant Acinetobacter baumannfi bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J. Hosp. Infect. (2003) 54(1):32–38.
  • JAIN R, DANZIGER LH: Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann. Pharmacother. (2004) 38(9):1449–1459.
  • WELSH MJ, TSUI L, BOAT T, BEAUDEN A: Cystic fibrosis. In: Metabolic and molecular basis of inherited disease (7th Edition). C Scriver, A Beaudet, D Valle, (Eds), McGraw-Hill, New York, NY, USA (1995).
  • CLANCY JP, BEBOK Z, RUIZ F et al.: Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. (2001) 163 (7) :1683–1692.
  • HOWARD M, FRIZZELL RA, BEDWELL DM: Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. (1996) 2(4):467–469.
  • KEREM E: Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr. Opin. Pulm. Med. (2004) 10(6):547–552.
  • WILSCHANSKI M, YAHAV Y, YAACOV Yet al.: Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl. J. Med. (2003) 349(15):1433–1441.
  • LEWIS C: Antiplasmodial activity of 7-halogenated lincomycins. j Parasitol. (1968) 54(1):169–170.
  • LEWIS C: Antiplasmodial activity of halogenated lincomycin analogues in Plasmodium berghei-infected mice. Antimicrob. Agents Chemother. (1967) 7:537–542.
  • CLYDE DF, GILMAN RH, MCCARTHY VC: Antimalarial effects of clindamycin in man. Am. J. Trop. Med. Hyg-.(1975) 24(2):369–370.
  • LELL B, KREMSNER PG: Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob. Agents Chemother. (2002) 46(8):2315–2320.
  • •Extensive review of clindamycin use as an antimalarial agent.
  • KREMSNER PG, ZOTTER GM, GRANINGER W, ROCHA RM, BIENZLE U, FELDMEIER H: Clindamycin is effective against Plasmodium falciparum but not against P vivax in mixed infections. Trans. R. Soc. Trop. Med. Hyg-. (1989) 83(3):332–333.
  • GINSBURG AS, GROSSET JH, BISHAI WR: Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. (2003) 3(7):432–442.
  • •Comprehensive review of fluoroquinolone use in tuberculosis and mechanisms of fluoroquinolone resistance in tuberculosis.
  • VON ROSENSTIEL N, ADAM D: Quinolone antibacterials. An update of their pharmacology and therapeutic use. Drugs (1994) 47(6):872–901.
  • BRYSKIER A, LOWTHER J: Fluoroquinolones and tuberculosis. Expert Opin. Investig. Drugs (2002) 11(2):233–258.
  • ALANGADEN GI, LERNER SA: The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin. Infect. Dis. (1997) 25(5):1213–1221.
  • BLUMBERG HM, BURMAN WI, CHAISSON RE et al.: American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. (2003) 167(4):603–662.
  • ••Comprehensive review of the recommendations to guide the treatment of tuberculosis in a setting where mycobacterial cultures, drug susceptiblities testing, radiographic facilities and second-line drugs are routinely available.
  • JI B, LOUNIS N, MASLO C, TRUFFOT-PERNOT C, BONNAFOUS P, GROSSET J: In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium Pasquale & Tan tuberculosis. Antimicrob. Agents Chemother.(1998) 42(8):2066–2069.
  • BERNING SE: The role of fluoroquinolones in tuberculosis today. Drugs (2001) 61(1):9–18.
  • Treatment of tuberculosis. MMWR Recomm. Rep. (2003) 52(RR-11):1–77.
  • LI J, NATION RL, MILNE RW, TURNIDGE JD, COULTHARD K: Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. Antimicrob. Agents (2005) 25(1):11–25.
  • •Good general review of colistin and the use of colistin for treatment of infections caused by MDR Gram-negative bacteria.
  • LIVERMORE DM: Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. (2002) 34(5):634–640.
  • LEVIN AS, BARONE AA, PENCO J et al.: Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannfi. Clin. Infect. Dis. (1999) 28(5):1008–1011.
  • LINDEN PK, KUSNE S, COLEY K, FONTES P, KRAMER DJ, PATERSON D: Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin. Infect. Dis. (2003) 37(11):e154–e160.
  • MARKOU N, APOSTOLAKOS H, KOUMOUDIOU Get al.: Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit. Care (2003) 7(5):R78–R83.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.